Publication Name	World Journal of Clinical Cases
Manuscript ID	79022
Country	China

Received	2022-08-09 05:02
Peer-Review Started	2022-08-09 05:04
To Make the First Decision
Return for Revision	2022-10-12 01:51
Revised	2022-10-13 05:12
Second Decision	2022-11-04 03:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-11-04 08:38
Articles in Press	2022-11-04 08:38
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-11-14 12:50
Publish the Manuscript Online	2022-12-02 12:50

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Case Report
Article Title	Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Xian Li, Xiao-Hong Pan, Qiu Fang and Yun Liang
ORCID	Author(s) ORCID Number Xian Li http://orcid.org/0000-0001-6380-7336 Xiao-Hong Pan http://orcid.org/0000-0003-3241-0250 Yun Liang http://orcid.org/0000-0002-9215-1708
Funding Agency and Grant Number
Corresponding Author	Yun Liang, MD, Chief Physician, Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, No 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. liangyun@zju.edu.cn
Key Words	Immunoglobulin light chain amyloidosis; Relapsed/refractory; Pleural effusion; Endo-myocardial biopsy; Immunomodulatory agent; Case report
Core Tip	We report the case of a 55-year-old man presenting with heart failure who was diagnosed with cardiac immunoglobulin light chain (AL) amyloidosis by an endomyocardial biopsy, in whom pomolidomide corrected severe pleural effusion after resistance to both bortezomib and daratumumab. This case emphasizes the crucial role of endomyocardial biopsy in early diagnosis of cardiac amyloidosis and suggests that pomolidomide may be an effective treatment for patients with AL amyloidosis that is relapsed/refractory to both bortezomib and daratumumab.
Publish Date	2022-12-02 12:50
Citation	Li X, Pan XH, Fang Q, Liang Y. Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report. World J Clin Cases 2022; 10(34):12703-12710
URL	https://www.wjgnet.com/2307-8960/full/v10/i34/12703.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i34.12703

Full Article (PDF)	WJCC-10-12703.pdf
Full Article (Word)	WJCC-10-12703.docx
CARE Checklist–2016	79022-CARE-Checklist–2016-revision.pdf
Manuscript File	79022_Auto_Edited-JLW.docx
Answering Reviewers	79022-Answering reviewers.pdf
Audio Core Tip	79022-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	79022-Conflict-of-interest statement.pdf
Copyright License Agreement	79022-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	79022-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	79022-Language certificate.pdf
Peer-review Report	79022-Peer-review(s).pdf
Scientific Misconduct Check	79022-Bing-Liu GL-2.png
Scientific Editor Work List	79022-Scientific editor work list.pdf